FDA Approves Benicar for the Hypertension Treatment in Children and Adolescents 6-16 old

FDA Approves Benicar for the Hypertension Treatment in Children and Adolescents 6-16 old.


US Food and Drug Administration (FDA) has approved the therapy of favourable blood press Benicar (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age plavix 75 mg price in tel-aviv superpharm. Benicar was at approved in 2002 for the care of hypertension in adults.



Approximately 5 percent, or 3,6 million, American children live from excited blood pressure, with the more than half ignorant they have the condition. Studies have also found that the norm blood pressing of American children is on the rise, in resemblance with the increase of children's weight rxlistplus. In fact, an enquiry of nearly 40 years of civil surveys of high blood lean on trends in children and adolescents showed that the prevalence of happy blood pressure among this group has been growing since the time 1980's.



A "As hypertension is on the make the grade also in a younger population, Daiichi Sankyo believes it is respected to help doctors meet the confrontation of treating these pediatric patients by providing a curing option to help people effectively run their hypertension," said Reinilde Heyrman, MD, Vice President Clinical Development - Operations, Daiichi Sankyo Pharma Development.



Pediatric hypertension is closely linked to minority obesity, as paunchy children are at approximately a three-fold higher peril for hypertension than non-obese children. Additionally hypertension during girlhood has been shown to be an sovereign hazard factor for hypertension in adulthood, and to be associated with dawn markers of cardiovascular disease, making it eminent to treat this health in children and adolescents.



The approval of this expanded suggestion was based on a phase III study examining the antihypertensive property of Benicar in pediatric patients. The examination found Benicar to be safe and serviceable in children ages 6-16 with hypertension, resulting in blood influence reductions that were statistically unalike in comparison to placebo. Benicar was generally well tolerated in pediatric patients, and the adverse happening sketch was similar to that for adults.



Benicar is an angiotensin II receptor blocker (ARB), which blocks the initiative of a essence in the body called angiotensin II that increases blood pressure. It is indicated for the healing of hypertension in adults as well as pediatric patients 6-16 years of age, solitarily or with other antihypertensive agents.



About Benicar. Angiotensin II is a hormone that interacts with a receptor on arterial blood vessels, which results in constriction and increasing blood pressure. In addition, angiotensin II stimulates the manumission of another hormone that causes enhanced sodium and chloride (salt) retention, with a resultant multiplication in vascular drench retention and blood quantity that also contributes to an rise in blood pressure. Benicar is a colleague of the ARB bearing of antihypertensive medications that alleviate deign blood coerce by blocking the angiotensin II receptor on the blood vessels, which may heroine to antagonizing the unveil of the hormone which causes taste retention and increased blood volume.



Benicar is indicated for the remedying of hypertension in adults and pediatric patients 6 to 16 years of age, simply or with other antihypertensive agents price of escapelle. Benicar may be occupied as commencing therapy.